Trillium Therapeutics Inc. (TRIL)
| Market Cap | 1.16B |
| Revenue (ttm) | 94,656 |
| Net Income (ttm) | -31.77M |
| Shares Out | 14.69M |
| EPS (ttm) | -2.90 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 1 |
| Last Price | $11.72 |
| Previous Close | $11.35 |
| Change ($) | 0.37 |
| Change (%) | 3.26% |
| Day's Open | 11.52 |
| Day's Range | 11.52 - 11.87 |
| Day's Volume | 561,371 |
| 52-Week Range | 2.50 - 20.96 |
Infinity Pharmaceuticals is my pick for Stock of the Year. And Shopify is my selection for Stock of the Decade.
The cancer biotech soared in 2020, jumping up over 1,000% for the year. What will the stock do in 2021?
Trillium Therapeutics has two lead candidates that encourage immune cells known as “macrophages” to gobble up cancer cells by blocking a protein known as CD47. However, the CD47 inhibitor spac...
Buy these three biotech stocks before they take off.
When it comes to countering a key trick that cancer plays on the human immune system, this biotech has no equal.
Biotech, bitcoin, and renewable energy led the way.
The company's long-term plan is to challenge conventional cancer therapy.
This clinical-stage biotech stock could be a top buyout candidate in 2021.
Find out what these healthcare businesses can do to deliver big gains this year.
The biopharma sector weathered the COVID-19 pandemic fairly well, with the Shares Nasdaq Biotechnology Etf (NASDAQ: IBB) outperforming the S&P 500 Index. This defensive sector also benefited f...
Investors need to pay close attention to Trillium (TRIL) stock based on the movements in the options market lately.
A decline in the stock price plus positive clinical data equals opportunity.
The highest performers of the year are biotechs fighting COVID-19 and cancer. Are they still buys for 2021?
Trillium Therapeutics (TRIL) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
A new CEO and prioritization of research could have more big gains in store for the company
CAMBRIDGE, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. ( “ Trillium ” or the “ Company ” ) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innov...
Biotech investors had more than just vaccines to think about this year.
Investors are catching on to the opportunity for this innovative cancer therapy, and so is big pharma.
CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of...
CAMBRIDGE, Ma., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative th...
Trillium Therapeutics has an encouraging pipeline with key differentiators that have attracted recent investor interest. The 2 major candidates, TTI-621 & 622 have shown monotherapy activity i...
Industry Veteran Brings Deep Executive and Commercial Experience to Trillium Board Industry Veteran Brings Deep Executive and Commercial Experience to Trillium Board
Adaptimmune Therapeutics and Trillium Therapeutics could be big winners for early shareholders.
CAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. ( “ Trillium ” or the “ Company ” ) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innov...
CAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative ...
CAMBRIDGE, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative ...
Investors need to pay close attention to Trillium (TRIL) stock based on the movements in the options market lately.
Industry Veteran Brings Deep Biologics Manufacturing Experience to Trillium Board Industry Veteran Brings Deep Biologics Manufacturing Experience to Trillium Board
CAMBRIDGE, Mass., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovati...
Trillium (TRIL) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Sorrento Therapeutics and Trillium Therapeutics could both be poised for another explosive move higher.
CAMBRIDGE, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovati...
CAMBRIDGE, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovati...
Shares of clinical stage immuno-oncology company Trillium Therapeutics Inc's (NASDAQ: TRIL) are trading higher on encouraging updated data from its ongoing lead cancer candidates TTI-622 and T...
Trillium lands a noteworthy equity stake from pharma titan Pfizer.
CAMBRIDGE, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX:TRIL), a clinical stage immuno-oncology company developing innovati...
CAMBRIDGE, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovati...
CAMBRIDGE, Mass., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovativ...
CAMBRIDGE, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX:TRIL), a clinical stage immuno-oncology company developing innovative...
Investors need to pay close attention to Trillium Therapeutics (TRIL) stock based on the movements in the options market lately.
CAMBRIDGE, Mass., July 06, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) (the “Corporation”), a clinical stage immuno-oncology company developing innovative therapie...
These are the biotech stocks with the best value, fastest growth, and most momentum for Q3 2020.
Trillium Therapeutics (NASDAQ: TRIL) shares are trading higher on Friday, after the company provided an update on TTI-622 at ASCO.
CAMBRIDGE, Mass., May 15, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...
CAMBRIDGE, Mass., May 06, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...
Investors need to pay close attention to Trillium (TRIL) stock based on the movements in the options market lately.
Trillium Therapeutics: Runup Expected For This CD47 Player Ahead Of Midyear Update
CAMBRIDGE, Mass., April 08, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovati...
About TRIL
Trillium Therapeutics, a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. Its product candidates also include TTI-622 that is in Phase I clinical trial of immunoglobulin G4 SIRPaFc protein; and TTI-10001, a small molecul... [Read more...]
| Industry Biotechnology | Founded 2004 |
| CEO Dr. Jan Skvarka | |
| Stock Exchange NASDAQ | Ticker Symbol TRIL |
Analyst Forecasts
According to 7 analysts, the average rating for TRIL stock is "Strong Buy." The 12-month stock price forecast is 11.02, which is a decrease of -5.97% from the latest price.